GleamWall
中文EN

BCRX BIOCRYST PHARMACEUTICALS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 882796 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY60.3%
TTM net income YoY-3,996.8%
TTM EPS YoY-2,460.0%
Revenue 3-yr CAGR44.7%
Net income 3-yr CAGR—

Margins

Gross margin97.9%
Operating margin-30.1%
Net margin-37.4%
FCF margin38.0%
EBITDA margin-29.9%

Returns

ROE—
ROA-69.3%
ROIC (approx.)—
Asset turnover1.85x

Leverage & solvency

Liabilities / assets167.2%
Debt / equity—
Current ratio2.71x
Interest coverage-3.77x

Cash quality & payout

Operating cash flow / net income-1.02x
Accruals ratio-140.2%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$180.29M$218.25M$156.41M$406.56M$159.40M$163.35M$145.53M$131.53M
Cost of revenue$1.57M$3.84M$5.38M$9.52M$2.19M$2.80M$4.57M$6.09M
Gross profit$178.72M$214.41M$151.04M$397.03M$157.21M$160.56M$140.97M$125.44M
R&D expense$58.21M$51.97M$60.32M$40.87M$44.60M$43.39M$37.27M$49.44M
SG&A expense$67.17M$63.98M$94.55M$95.78M$83.01M$87.38M$82.47M$80.51M
Operating income$53.33M$98.47M-$701.60M$260.38M$29.59M$29.79M$21.23M-$4.51M
Interest expense$21.18M$21.71M$19.78M$14.13M$19.66M$21.58M$23.49M$24.45M
Pretax income$38.59M$79.47M-$720.81M$248.02M$12.13M$6.49M$758,000-$25.99M
Income tax$669,000$1.08M$1.00M$2.17M-$769,000$1.40M$726,000$804,000
Net income$37.92M$78.39M-$721.81M$245.84M$12.90M$5.08M$32,000-$26.80M
EBITDA$53.57M$98.98M-$701.14M$260.78M$29.93M$30.11M$21.56M-$4.20M
EPS (basic)0.150.31-2.98—0.060.020.00—
EPS (diluted)0.140.30-2.98—0.060.020.00—
Weighted avg. shares (diluted)267.62M265.17M242.26M—219.88M219.89M215.26M—
Balance sheet
Cash & equivalents$96.97M$154.97M$171.59M$89.74M$84.08M$88.03M$105.19M$106.32M
Short-term investments$278.03M$197.60M$66.81M$185.01M$128.79M$172.00M$189.90M$216.14M
Receivables$121.79M$110.76M$109.27M$106.82M$91.33M$91.18M$93.39M$79.07M
Inventory$13.74M$6.06M$5.99M$5.40M$5.23M$5.04M$6.87M$8.09M
Current assets$531.15M$484.68M$373.62M$404.35M$355.68M$398.46M$409.98M$421.97M
PP&E, net$1.66M$9.06M$9.37M$8.78M$8.40M$8.46M$7.59M$7.78M
Total assets$591.07M$557.85M$465.05M$514.16M$446.42M$457.19M$480.05M$490.42M
Current liabilities$195.83M$208.85M$195.39M$196.07M$190.24M$177.16M$139.85M$160.38M
Long-term debt$395.61M$395.40M$395.20M$0$194.37M$242.79M$315.41M$314.87M
Total debt$395.61M$395.40M$395.20M$0$194.37M$242.79M$315.41M$314.87M
Total liabilities$988.45M$1.01B$1.02B$633.31M$834.31M$878.78M$931.97M$966.35M
Shareholders' equity-$397.38M-$454.29M-$553.84M-$119.15M-$387.89M-$421.59M-$451.93M-$475.93M
Net debt$298.64M$240.43M$223.61M-$89.74M$110.29M$154.76M$210.22M$208.55M
Shares outstanding256.12M255.26M254.01M213.06M210.52M209.91M209.21M208.54M
Cash flow statement
Operating cash flow$32.98M$104.34M-$61.79M$291.96M$41.62M$41.30M-$27.52M-$5.21M
Capital expenditure$233,000$209,000$403,000$802,000$1.34M$179,000$143,000$675,000
Free cash flow$32.75M$104.13M-$62.19M$291.16M$40.28M$41.12M-$27.66M-$5.89M
Investing cash flow-$78.88M-$110.15M-$268.65M-$83.49M$13.57M$29.13M$27.09M$17.80M
Financing cash flow-$12.08M-$11.15M$412.55M-$217.96M-$58.81M-$73.69M$529,000-$4.02M
Depreciation & amortization$244,000$513,000$461,000$394,000$335,000$329,000$331,000$309,000
Stock-based compensation$14.24M$14.69M$16.03M$23.79M$18.60M$21.30M$21.37M$21.34M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.